- Citi 16th Annual
BioPharma Virtual Conference – Pliant’s senior management team will participate in one-on-one meetings with members of the investment communitySeptember 8 - 9, 2021 - Cantor 2021
Virtual Global Healthcare Conference –Bernard Coulie , M.D., Ph.D., Pliant’s President and Chief Executive Officer, will present onWednesday, September 29, 2021 , at2:40 p.m. ET /11:40 a.m. PT and, along with members of Pliant’s senior management team, will participate in one-on-one meetings with members of the investment community
The webcast replay of the Cantor conference presentation will be archived for 90 days following the conclusion of the event.
About Pliant Therapeutics, Inc.
Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
ir@pliantrx.com
Source:
2021 GlobeNewswire, Inc., source